Genmab A/S (OTCMKTS:GNMSF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage currently has a $196.00 price target on the stock. Zacks Investment Research’s price objective would suggest a potential upside of 12.55% from the stock’s current price.
According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “
Shares of Genmab A/S (OTCMKTS:GNMSF) remained flat at $174.15 during midday trading on Tuesday. The company has a market capitalization of $10.49 billion, a P/E ratio of 100.78 and a beta of 1.11. Genmab A/S has a 52-week low of $94.74 and a 52-week high of $183.00. The company’s 50-day moving average is $165.54 and its 200-day moving average is $168.00.